<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01769768</url>
  </required_header>
  <id_info>
    <org_study_id>CLDE225A2112</org_study_id>
    <nct_id>NCT01769768</nct_id>
  </id_info>
  <brief_title>Phase I Study to Evaluate the Effect of LDE225 on the Pharmacokinetics of Bupropion and Warfarin in Patients</brief_title>
  <official_title>A Phase Ib, Multi-center, Two Parallel Group, Open-label, Drug-drug Interaction Study to Assess the Effect of LDE225 on the Pharmacokinetics of Bupropion and Warfarin in Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi center, open-label study to evaluate the drug-drug interaction of LDE225 on
      the PK of bupropion and warfarin patients with advanced solid tumors. Subjects will receive
      800mg daily of LDE225 and two separate doses of either bupropion or warfarin.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">August 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics (PK) parameter AUClast for S- and R-warfarin</measure>
    <time_frame>7 days</time_frame>
    <description>Pharmacokinetics of warfarin : Maximum observed plasma concentration after drug administration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameter AUClast for bupropion</measure>
    <time_frame>7 days</time_frame>
    <description>Pharmacokinetics bupropion : Maximum observed plasma concentration after drug administration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameter AUCinf for bupropion</measure>
    <time_frame>7 days</time_frame>
    <description>Pharmacokinetics of bupropion : Maximum observed plasma concentration after drug administration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameter AUCinf for S- and R-warfarin</measure>
    <time_frame>7 days</time_frame>
    <description>Pharmacokinetics of warfarin and bupropion : Maximum observed plasma concentration after drug administration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameter Cmax for S- and R-warfarin</measure>
    <time_frame>7 days</time_frame>
    <description>Pharmacokinetics of warfarin : Maximum observed plasma concentration after drug administration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameters Cmax for bupropion</measure>
    <time_frame>7 days</time_frame>
    <description>Pharmacokinetics of Bupropion : Maximum observed plasma concentration after drug administration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>effects of LDE225 on the pharmacodynamic activity of warfarin</measure>
    <time_frame>7 days</time_frame>
    <description>INR parameter (International Normalized Ratio) will be assessed to evaluate the pharmacodynamic effect of warfarin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>safety of LDE225 when administered alone and concomitantly with either bupropion or warfarin</measure>
    <time_frame>28 days cycles</time_frame>
    <description>safety laboratory parameters, adverse event reports, changes in vital signs, changes in physical examination parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>evaluate the preliminary evidence of anti-tumor activity of LDE225 in patients with advanced solid tumors</measure>
    <time_frame>every other cycle</time_frame>
    <description>CT or MRI imaging parameters to determine the objective response rate according to RECIST 1.1 (Response Evaluation Criteria In Solid Tumors)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>assess the effect of LDE225 treatment on cardiac function</measure>
    <time_frame>screening, cycle 4 and EOT</time_frame>
    <description>ECGs will be performed to determine the effect of LDE on the cardiac function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>effects of LDE225 on the pharmacodynamic activity of warfarin</measure>
    <time_frame>7 days</time_frame>
    <description>PT (Prothrombin time) parameter will be assessed to evaluate the pharmacodynamic effect of warfarin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>safety of LDE225 when administered alone and concomitantly with either bupropion or warfarin</measure>
    <time_frame>28 days cycles</time_frame>
    <description>safety laboratory parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>safety of LDE225 when administered alone and concomitantly with either bupropion or warfarin</measure>
    <time_frame>28 days cycles</time_frame>
    <description>adverse event reports</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>safety of LDE225 when administered alone and concomitantly with either bupropion or warfarin</measure>
    <time_frame>28 days cycles</time_frame>
    <description>changes in vital signs</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">114</enrollment>
  <condition>Advanced Solid Tumor</condition>
  <arm_group>
    <arm_group_label>LDE225+Warfarin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>At least 15 evaluable patients with advanced solid tumors will be enrolled into the study into the warfarin group.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LDE225+Bupropion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>At least 15 evaluable patients with advanced solid tumors will be enrolled into the study into the Bupropion group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LDE225</intervention_name>
    <description>LDE225 800 mg once daily dosing will begin on Cycle 1 Day 1 of a 28-day cycle.Treatment with LDE225 for both groups will continue until the patient experiences unacceptable toxicity that precludes further treatment, disease progression, withdrawal of consent and/or at the discretion of the investigator.</description>
    <arm_group_label>LDE225+Warfarin</arm_group_label>
    <arm_group_label>LDE225+Bupropion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Wafarin</intervention_name>
    <description>15 mg single dose of warfarin (oral tablet) will be given to patients.</description>
    <arm_group_label>LDE225+Warfarin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupropion</intervention_name>
    <description>75 mg single dose of bupropion(oral tablet, from an immediate release formulation) will be given to patients</description>
    <arm_group_label>LDE225+Bupropion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults

          -  Patients with cytopathologically or histopathologically confirmed diagnosis of an
             advanced solid tumor which has progressed despite standard therapy, or for which no
             standard therapy exists or patients with locally advanced or metastatic basal cell
             carcinoma who are not amendable or eligible for standard therapy.

          -  Protocol-defined renal , liver and bone marrow function

        Exclusion Criteria:

          -  CNS (Central Nervous System) tumors as well as history of brain metastases

          -  Systemic anticancer treatment (including biologic therapy/antibodies) within 2 weeks
             before first dose of study treatment (6 weeks for nitrosourea, mitomycin, and
             monoclonal antibodies).

          -  Radiation therapy within 4 weeks before first dose

          -  Investigational agents within 4 weeks before start of study therapy

          -  Patients with known allergy/hypersensitivity to warfarin or bupropion and/or related
             compounds

          -  Patients with a history of/or active bleeding disorders

          -  Patients receiving treatment with vitamin K, Coumadin or other agents containing
             warfarin and heparin. Heparin flush to maintain patency of a central venous access
             device is allowed.

          -  Patients receiving treatment with bupropion.

          -  Patients who have neuromuscular disorders that are associated with elevated CK
             (Creatine phosphokinase) (e.g., inflammatory myopathies, muscular dystrophy,
             amyotrophic lateral sclerosis, spinal muscular atrophy).

          -  Known diagnosis of human immunodeficiency virus (HIV), Hepatitis B or C (testing is
             not mandatory for study entry)

          -  Patients currently receiving systemic corticosteroids

        Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>City of Hope National Medical Center Oncology</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center CBYM338B2203</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dartmouth Hitchcock Medical Center Dartmouth-Hitchcock Med Ctr</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center Dept.of HackensackUniv.MedCtr.</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania--Abramson Cancer Center Abramson Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111-2497</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Cancer Institute UPMC Cancer Pavilion</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina Dept.of Neurosciences/MS Ctr.</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Centers of the Carolinas SC</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Utah Health Science Center at San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah / Huntsman Cancer Institute</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 15, 2013</study_first_submitted>
  <study_first_submitted_qc>January 15, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 17, 2013</study_first_posted>
  <last_update_submitted>February 3, 2017</last_update_submitted>
  <last_update_submitted_qc>February 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Adults, Hh (Hedgehog) pathway inhibitor, LDE225, Warfarin, Bupropion, advanced solid tumor, drug-drug interaction, pharmacokinetic</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Warfarin</mesh_term>
    <mesh_term>Bupropion</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

